

Group I. Claims 1-8 and 13-22, drawn to a method for inhibiting and preventing a malignant cell phenotype, method for treating cancer, comprising administering a low dose of a nitric oxide mimetic.

Group II. Claims 9-12, drawn to a formulation comprising a nitric oxide mimetic.

Group III. Claims 23-25, drawn to a method for prophylactically inhibiting and prevent[ing] a malignant cell phenotype in animals at high risk for developing cancer comprising administering a low dose of a nitric oxide mimetic.

Group IV. Claims 26-29, drawn to a method of monitoring or diagnosing the progression of a tumor in a patient comprising measuring a level of a tumor marker in the presence of a low dose of a nitric oxide mimetic.

#### REMARKS

Claims 1-29 are pending in this application and presented for examination. Claims 30-32 have been canceled without prejudice. The pending claims are set forth in the appendix. Attached hereto is a marked-up version of the changes made to the s claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

Applicants hereby elect Group I, with traverse, drawn to a method for inhibiting and preventing a malignant cell phenotype, method for treating cancer, comprising administering a low dose of a nitric oxide mimetic, with traverse. Claims readable thereon include claims 1-8 and 13-22.

As to the species election, Applicants hereby elect GTN (glyceryl trinitrate).

Applicants traverse the restriction requirement as the two criteria for a proper restriction requirement have not been met. Under M.P.E.P. § 803, to be proper, the inventions must be independent or distinct; and there must be a serious burden on the Examiner.